Is there a future for cancer chemotherapy?

Annals of Oncology

Volumn 7, Issue 5, 1996, Pages 445-452

  Connors, T A ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

ADEPT; Antibodies; Bioreductives; Cancer chemotherapy; Chemoprevention; Gene therapy; Polymers; Vaccines

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; METHOTREXATE; MITOMYCIN; MONOCLONAL ANTIBODY; NEW DRUG; VINBLASTINE;

CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; FUTUROLOGY; GENE THERAPY; HUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0030036503     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010632     Document Type: Short Survey

References (25)

1. Kerr DJ, Kaye SB, Cassidy J et al. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res 1987; 47: 6447-50.
2. Ching L-M, Joseph WR, Zhuang L et al. Induction of natural killer activity by xanthenone-4 acetic acids; correlation with antitumour activity. Eur J Cancer 1991; 27: 79-83.
3. Chaplin D. Personal communication.
4. Bagshawe KD. Antibody directed enzymes revive anti-cancer prodrug concept. Br J Cancer 1987; 65: 531-2.
5. Connors TA, Knox RJ. Prodrugs in cancer chemotherapy. Stem Cells 1995; 13: 501-11.
6. Maeda H. SMANCS and polymer conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv Drug Delivery Res 1992; 6: 181-202.
7. Duncan R. Drug polymer conjugates: Potential for improved chemotherapy. Anti Cancer Drugs 1992; 3: 175-210.
8. O'Hare KB, Duncan R, Strohalm J et al. Macromolecular prodrugs containing doxorubicin and melanocyte stimulating hormone in vitro and in vivo evaluation against murine melanoma. J Drug Targeting 1993; 1: 217-30.
9. Hendriks HR, Pizao PE, Berger DP et al. EO9 a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 1993; 29: 897-991.
10. Hodgkiss RJ, Stratford MRL, Dennis MF, Hill SA. Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: Effect of route of administration. Br J Cancer 1995; 72: 1462-8.
11. 19F NMR relaxometry of a perfluorocarbon emulsion. Magn Reson Med 1993; 29: 303-10.
12. Durrant L. Anti-idiotypic tumor immunotherapy. Tumor Targeting 1995; 1: 65-6.
13. Riethmuller G, Schneider-Gadicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Duke's C colorectal carcinoma. Lancet 1994; 343: 1177-83.
14. Vuist MJ, Levy R, Maloney DG. Lymphoma regression induced by monoclonal anti-idiotype antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumour expression of high levels of BCL2. Blood 1994; 83: 899-906.
15. Fritzberg AR, Beaumier PL, Bottino BJ, Reno JM. Approaches to improved antibody and peptide mediated targeting for imaging and therapy of cancer. J Controlled Release 1994; 28: 167-73.
16. MJ Glennie. Personal communication.
17. Wallace PK, Valone FH, Fanger MW. Myeloid cell-targeted cytotoxicity of tumor cells. In Fanger MW (ed): Bispecfic Antibodies. RG Landes Company 1995; 43-76.
18. Douglas JT, Curiel DT. Targeted gene therapy. Tumor Targeting 1995; 1: 67-84.
19. Connors TA. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther 1995; 2: 702-9.
20. Burger A, Double JA. Personal communication.
21. Todorov P, Cariuk P, McDevitt T et al. Characterisation of a cancer cachectic factor. Nature 1966; 379: 739-42.
22. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu Rev Biochem 1993; 62: 453-82.
23. Graham SL. Inhibitors of protein farnesylation: A new approach to cancer chemotherapy. Expert Opinion on Therapeutic Patents 1995; 5: 1269-85.
24. Crowell PL, Chang RR, Ren Z et al. Selective inhibition of isoprenylation of 21-26 kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem 1991; 266: 17679-85.
25. Domin J, Higgins T, Rozengurt E. Preferential inhibition of platelet derived growth factor stimulated DNA synthesis and protein tyrosine phosphorylation by nordihydroguaiaretic acid. J Biol Chem 1994; 269; 8260-7.